Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

STAG2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

STAG2 underexpression (2)

STAG2 underexpression (2)

›

STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
STAG2 mutation	Colorectal Cancer	STAG2 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
STAG2 mutation	Glioblastoma	STAG2 mutation	Glioblastoma	olaparib Sensitive: D – Preclinical olaparib Sensitive : D	olaparib Sensitive: D – Preclinical olaparib Sensitive : D